Terremoto Biosciences utilizes lysine-based covalency to expand the range of drug targets for small molecule medicines, enhancing their therapeutic efficacy. This approach addresses the limitations of traditional covalent drugs, which primarily target cysteine, by enabling the development of more effective treatments for various diseases.
Funding
$250M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Traditional covalent drugs are limited in their target range, primarily focusing on cysteine residues, which restricts the development of effective treatments for a wide array of diseases. This limitation hinders the ability to create small molecule medicines with enhanced therapeutic efficacy.
Solution
Terremoto Biosciences is expanding the druggable target space by utilizing lysine-based covalency to develop small molecule medicines. Their technology overcomes the limitations of conventional covalent drugs by targeting lysine, an amino acid with unique chemical properties. This approach allows for the creation of more selective and effective covalent drugs, potentially improving treatment outcomes across various therapeutic areas. By broadening the scope of covalent drug design, Terremoto aims to deliver superior therapeutics with enhanced benefits for patients.
Target Audience
The primary target audience includes pharmaceutical companies and researchers focused on developing novel small molecule therapeutics for various diseases.
Features
- Lysine-based covalency platform expands the range of druggable targets beyond cysteine.
- Enables the development of more selective and effective covalent drugs.
- Enhances the therapeutic efficacy of small molecule medicines.